Cleared Dual Track

K223591 - cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Liat® System (FDA 510(k) Clearance)

Class II Microbiology device cleared through the Dual Track 510(k) pathway - typically does not require clinical trials.

K223591 · Roche Molecular Systems, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2023
Decision
238d
Days
Class 2
Risk

K223591 is an FDA 510(k) clearance for the cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Lia.... Classified as Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents (product code QOF), Class II - Special Controls.

Submitted by Roche Molecular Systems, Inc. (Pleasanton, US). The FDA issued a Cleared decision on July 27, 2023 after a review of 238 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3981 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Roche Molecular Systems, Inc. devices

Submission Details

510(k) Number K223591 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 01, 2022
Decision Date July 27, 2023
Days to Decision 238 days
Submission Type Dual Track
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
136d slower than avg
Panel avg: 102d · This submission: 238d
Pathway characteristics

Device Classification

Product Code QOF Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3981
Definition A Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The Sars-cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-target Test Is An In Vitro Diagnostic Device Intended For The Detection And Identification Of Sars-cov-2 And Other Microbial Agents When In A Multi-target Test In Human Clinical Respiratory Specimens From Patients Suspected Of Respiratory Infection Who Are At Risk For Exposure Or Who May Have Been Exposed To These Agents. The Device Is Intended To Aid In The Diagnosis Of Respiratory Infection In Conjunction With Other Clinical, Epidemiologic, And Laboratory Data Or Other Risk Factors.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - QOF Multi-target Respiratory Specimen Nucleic Acid Test Including Sars-cov-2 And Other Microbial Agents

All 30
Devices cleared under the same product code (QOF) and FDA review panel - the closest regulatory comparables to K223591.
VELO Respiratory Test
K251742 · Lex Diagnostics Limited · Feb 2026
LIAISON NES FLU A/B, RSV & COVID-19
K251978 · Diasorin Molecular, LLC · Dec 2025
Simplexa™ COVID-19/ Flu A/B & RSV Direct (MOL4450)
K252387 · Diasorin Molecular, LLC · Oct 2025
QIAstat-Dx Respiratory Panel Plus
K250080 · QIAGEN GmbH · Aug 2025
BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini
K243544 · Biofire Diagnostics, LLC · Aug 2025
cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 Systems
K243455 · Roche Molecular Systems, Inc. · Jul 2025